Olaris Announces Findings from Exploratory Analysis of Biomarkers that Predict Patient Responsiveness to Trastuzumab Therapy
Olaris’ metabolite profiling platform and machine learning algorithms have the potential to accurately indicate whether HER2-positive metastatic breast cancer patients will respond to trastuzumab therapy WALTHAM, MASS. (PRWEB) MARCH 02, 2020 Olaris, a precision medicine company that is working to fundamentally change how diseases are treated, today announced the findings from[…]
Read more